Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of XP19986 in Subjects With Acute Back Spasms
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Arbaclofen placarbil (Primary)
- Indications Back pain; Spasm
- Focus Adverse reactions
- Sponsors XenoPort
- 16 Sep 2014 New trial record